<SEC-DOCUMENT>0001299933-12-002152.txt : 20120919
<SEC-HEADER>0001299933-12-002152.hdr.sgml : 20120919
<ACCEPTANCE-DATETIME>20120919094544
ACCESSION NUMBER:		0001299933-12-002152
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120919
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20120919
DATE AS OF CHANGE:		20120919

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		121098895

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>htm_46038.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> Cumberland Pharmaceuticals Inc. (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<!-- Comment1 -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	September 19, 2012
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	Cumberland Pharmaceuticals Inc.
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Tennessee
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	001-33637
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	62-1765329
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	2525 West End Avenue, Suite 950, Nashville, Tennessee
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	37203
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	(615) 255-0068
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 8.01 Other Events.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
On September 19, 2012, Cumberland Pharmaceuticals Inc. issued a press release announcing top-line results from a clinical pediatric study evaluating the safety and analgesic efficacy of Caldolor(R)(ibuprofen) Injection in treating pain in tonsillectomy patients ranging from 6 to 16 years old.  A copy of the press release is attached as Exhibit 99.1.
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><P ALIGN="LEFT" STYLE="FONT-SIZE: 10PT"></P><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	Cumberland Pharmaceuticals Inc.
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	September 19, 2012
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Rick S. Greene
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: Rick S. Greene
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: Chief Financial Officer
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Press release dated September 19, 2012
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-99.1 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt"><img src="e36977-12262174255159b8e2_1.jpg">
</FONT>

<P align="center" style="font-size: 12pt"><B>CALDOLOR</B><sup><B><FONT style="font-family: Symbol">&#210;</FONT></sup> REDUCES NARCOTIC DOSES<BR>
IN PEDIATRIC PAIN PATIENTS</B>



<P align="center" style="font-size: 12pt"><I>- Study demonstrates Caldolor significantly reduces the number of post-operative narcotic doses</I>



<P align="left" style="font-size: 12pt"><B>NASHVILLE, Tenn. &#150; September&nbsp;19, 2012 &#150; Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) </B>today
announced top-line results from a clinical pediatric pain study evaluating the safety and analgesic
efficacy of <B>Caldolor</B><sup><FONT style="font-family: Symbol"><B>&#210;</B></FONT></sup><B> (</B><B><I>ibuprofen</I></B><B>) Injection </B>in treating pain in tonsillectomy
patients ranging from 6 to 16&nbsp;years old.


<P align="left" style="font-size: 12pt">When administered prior to surgery, Caldolor use was associated with a statistically significant
reduction in the number of post-operative narcotic doses required in patients in the efficacy
evaluable population. There were also consistent trends toward reduction in pain scores and the
incidence of nausea and vomiting in patients receiving Caldolor. Importantly, no safety concerns
were observed during this study.


<P align="left" style="font-size: 12pt">&#147;We remain committed to the ongoing development of an approved product, including studies
evaluating them in new patient populations,&#148; said A.J. Kazimi, Chief Executive Officer of
Cumberland Pharmaceuticals. &#147;We are pleased to complete the first of our phase IV Caldolor
studies.&#148;


<P align="left" style="font-size: 12pt">This study, in combination with the ongoing work to evaluate the treatment of fever in children,
will be used to pursue a pediatric indication for Caldolor.


<P align="left" style="font-size: 12pt">SOURCE: Cumberland Pharmaceuticals Inc.


<P align="left" style="font-size: 12pt"><B>About Caldolor</B>


<P align="left" style="font-size: 12pt">Caldolor is indicated for the management of mild to moderate pain and management of moderate to
severe pain as an adjunct to opioid analgesics, and for the reduction of fever in adults. It is the
first FDA approved intravenous therapy for fever. Caldolor is contraindicated in patients with
known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic
type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the
peri-operative period in the setting of coronary artery bypass graft (CABG)&nbsp;surgery. Caldolor
should be used with caution in patients with prior history of ulcer disease or GI bleeding, in
patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart
failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be
monitored during treatment with Caldolor. For full prescribing information, including boxed
warning, visit <U>www.caldolor.com</U>.


<P align="left" style="font-size: 12pt"><B>About Cumberland Pharmaceuticals</B>


<P align="left" style="font-size: 12pt">Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on
the acquisition, development and commercialization of branded prescription products. The Company&#146;s
primary target markets include hospital acute care and gastroenterology. Cumberland&#146;s marketed
products include Acetadote<sup>&#174;</sup> (<I>acetylcysteine</I>) Injection for the treatment of
acetaminophen poisoning, Caldolor<sup>&#174;</sup> (<I>ibuprofen</I>) Injection, the first injectable treatment
for pain and fever approved in the United States, and Kristalose<sup>&#174;</sup> (<I>lactulose</I>) for Oral
Solution, a prescription laxative. Cumberland is dedicated to providing innovative products which
improve quality of care for patients. For more information, visit the Company&#146;s website at
<U>www.cumberlandpharma.com</U>.


<P align="left" style="font-size: 12pt"><B>Important Note Regarding Forward-Looking Statements</B>


<P align="left" style="font-size: 12pt">This press release contains forward-looking statements that reflect Cumberland&#146;s current views on
future events, based on what it believes are reasonable assumptions. No assurance can be given that
these events will occur. As with any business, all phases of operations are subject to influences
outside of the Company&#146;s control. Risk factors that could materially affect results of operations
include market conditions, competition from existing and new products, an inability or failure of
manufacturers to produce the Company&#146;s products on a timely basis or to comply with stringent
regulations applicable to drug manufacturers, maintaining and building an effective sales and
marketing infrastructure, government regulation, the possibility that patent rights may provide
limited protection from competition, and other factors including those under the headings &#147;Risk
factors&#148; and &#147;Management&#146;s discussion and analysis of financial condition and results of
operations&#148; in Cumberland&#146;s Form 10-K filed with the SEC on March&nbsp;11, 2011. There can be no
assurance that results anticipated by Cumberland will be realized or, if realized, that they will
have the expected effects. Readers are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date hereof. Cumberland undertakes no obligation to release
publicly any revisions to these statements to reflect events or circumstances after the date
hereof.


<P align="left" style="font-size: 12pt"><U>Investor Contact:</U>
<BR>
Elizabeth Davis
<BR>
Corporate Relations
<BR>
Cumberland Pharmaceuticals
<BR>
615-255-0068
<BR>
<U>edavis@cumberlandpharma.com</U>

<DIV align="center">
<TABLE style="font-size: 12pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="34%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 12pt">
    <TD colspan="3" valign="top" align="left">Media Contact:<BR></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="5" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;<BR></TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD colspan="3" valign="top" align="left">Rebecca Kirkham<BR></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD colspan="5" valign="top" align="left">Lovell Communications<BR></TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD colspan="3" valign="top" align="left">615-297-7766<BR></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD colspan="3" valign="top" align="left">rebecca@lovell.com<BR></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="5" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;<BR></TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">#
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">#
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">#</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt; display: none">




<!-- v.121908 -->
</BODY>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>e36977-12262174255159b8e2_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 e36977-12262174255159b8e2_1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!;`9$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^^BBBB@`H
MIK.B!F=@JJK,S,0%554NQ9C@*`H)))`P#7S7\1/VK?A5\/\`3YK^*XU?QP((
MHIVC\#V$>IVDL3WNH:=<&U\2ZC=Z3X,N[G2[[3+NVU?1[3Q+/KNGNL?VC2T$
ML9;2E1JUYJ%&E.I-M)1@KMM[>FZWLK:[:B;2W=O4^EJ\KTCXM^&]:^,OCOX)
MV3"7Q1\/?A]\-_B)X@9)2ZV^E_%#7OB;H/AVUDC\E4BNFF^%FOW3I]IDE^RR
MV<KP11SPR3?@I^UU_P`%NO'G@+2M<TGX)_!W0-)U?RC'IWBSXB:W<^(HH(_W
MRW$LG@K0K;1(EOC"5-E))XSU&QM;M4>[T_5+59K>?Y__`.#;OXL?$?XY_'7_
M`(*8?%;XM>+=5\<_$+QE>_LT:CXC\3:Q)&;N_GC3X[65I!%;VT-M8:;INF:?
M;6FF:1H^F6EGI.B:59V>E:79VFGVEO`GV"X)S3#\/YIG^8QIX:A@Z.&>&HJJ
MJE:K6Q&-PN'4I1I.<(4X4ZLY6E4YW/E2A9<QX]?-Z<,PR_+Z2<YXNM4C.36D
M(4L/5K-*[3YW.$5==&_1_P!7]%`X`'I17Q9[(4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%>0?'#XX?#[]GWX?ZI\1/B+K`T
M[2;%H[/3["V6.XUOQ+KMTDC:;X:\.:>\L`U#6M3,,S11R3VUE965O>ZQK%]I
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M(]1MHM`L)++39-(T&QU*VO=5U/T+]H["^$8<``+ID("JHZ")E4``<`9&!T'&
M!QD=1^SW_P`$_O&O@6ST^X^(/Q"T&QO$CNTO-'\#:9=:R(I%O&&GW=GXL\0C
M28F,]@%>]T^X\!S1VMZ[Q0ZC>0PK//\`8NJ?LL_#/Q/I#Z-XZG\6>-K9MJ)/
MJ'B2]\-7D-NA4K;Q3_#K_A"@$!4Y=T>=MS*\K)A1UXS&Y7A\QH2P4XRPF%=H
M*C!VTDKN+E&"FY<MY3<KR;NVVVW5.-3V;YE[TN5N[UOU_P"!K]Y_$#^UYS/J
M77A)OYMGZ8]\8K]#O^#67Y?&?_!0?/<?LU8_&;X]?ECJ<XP.M?TJ6O[#/[(,
M-M]DOOV<_A-XFBVNA;QUX1T[XA7#K)][S;OQS'XANY6]'DG=P<G=R:_(;_@I
M%X"\$_LB>)/AG-^RCX0\+_LR2_$#1/$LGCM_V?=`TOX,OXTE\.7VD+X=F\6/
M\.K7PZWB&701K6M+HTFK&[?2UU?4UL3`+^[\[ZG-_$#`X_AG'</T<OQ4:F+C
MA(QQ-2=&-.#P^*P^(DY4HRJ2:DJ+BN66\DVM+/Q7DM5YI@<P]M34<)4JSE3Y
M9N4_:8>=)<LM$G&4TWS)W47WT_HFR/7^G\^M%?Q<:%^WE^V'\/+B:Y\/?M!_
M$6Z>8;7C\8:LGQ$M@$V2?NK7Q_!XF@MMQ15+6L<#["Z!@':OMSX+_P#!=+X@
M>']1T_1OVA/AAHOC31))[.UN?%?PX<^&O%EE`2PN+^?P[JUW=^'/$5W(?+"6
M=IJ/@FW0&203MA8Q^5'T1_3717@_P%_:5^#7[2?AK_A)OA+XPM-?A@B@?5-%
MN(Y=-\3Z"]P&$<6MZ#>K%?6:O)'/#!?HD^DZA+;7!TO4+Z*)I:]XH`*0D#K^
M>.*6OYGO^"S7_!5#]LC]FO\`:Y_9H_84_8A\-^`&^+GQX\->%/$*^(_'6G6>
MKRZCJ_Q&^(>O_#?P#X1T)=<U72O"N@Q/J_A/6KKQ!K7B&*_B>#4=*6!]&CLK
MR?4/7R/),9Q!F$,NP+P\*KI5L14K8JM&AAJ&'P]-U*U:M5DFH0A!7;2;ZI.S
M/-S;-<+D^$>,Q?M73]K1HQA0A[6M4JUZD:5*G3A]J4YR2Z??9/\`I?W+Z_Y_
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M0RZ_;#B_:6\1>%M>3X,7_P`$;;P,/#/@[2?"?V6+QR_QF7Q`-1.EJIU-IAX*
MT+[,]QS:^5<&/)N9#7S.%R;&8O+,WS6E[%8;))8&.-4YM55+'UYX>A&E!1:F
MU4IS]IS2ARI)ZWL>[B,UPN&Q^6Y?4]HZ^:K%/"N$4Z?^R48UZOM)-IQ3A-<E
MHRYI>Z[;K^DBBD.3Z>^?_P!8K^;K4/\`@I1^U3;?\'#&@_\`!.F/Q)X5'[,M
M_I\MU<:%_P`(9I!\4-(/V.M6^-"X\7,K:HJCQQ9076%(_P!`4Z=_Q[NX:<KR
M?&9Q+'QP;HIY;EF,S;$^VG*'^R8*,)5O9VA+FJVG'V<-%+WKM65S,<TPV5QP
ML\5[2V,QV&R^BJ<>=O$8IM4N?WH\L+Q?-+6UXVWT_I%R/7U'Y?Y_'M1GO@]<
M?_7Y[5\]?M;?$+Q-\(_V5?VEOBOX*N;:S\9?#+X`_&#XA>$[N]M(=0L[?Q)X
M,^'WB'Q'HD]W87`:WO;:+4]/MI)[28-%<1*T3@HQ%?@7_P`$)?\`@MIXY_;E
M\1>+?V=OVMK[PQ8?'\V]SXX^$/B#1]'M?"&D_%#P+81W$/BGP]9:-$%T^7Q3
MX(N=/NM6\W3[J277_#<VK3#3K5_`NMZAJ73@N',TS#)\SSO"4X5L'E%6C#&Q
M4W]8A"M%R56%+EM4I4U&3KM34J<'[3E<(2:RQ6=X'!YI@,IQ$YPQ.9TZL\(W
M']S*5%QO2G43O"I4YDJ2<;2<E&_.TC^GJBDSQGCIZ\?GCI[XZ<XK^4'_`(+K
M_P#!=/XH_L7_`!D\)?LQ?L=ZSX17XH>&M-@\5_'?Q1KWAS3O%]GX:'B'3H;G
MP7\/+2PU&9K2WUJYTB[7QEXAN)+0SVNGZCX,AT^\'V[7+6..'^'\SXFS&GE>
M54X5,14A.I*=6;IX>C2A;FK5ZD83<(<THP347S3G"*3<DB\YSG`Y#@:F88^<
MHT824(QIQ4ZM6I)Z4Z4.:/-+E4IO6RIPG-Z1;7]7V1SUX]C_`)_SGIS1D?YP
M#^N*\2_9I\;>(/B=^SE\`OB1XLGM[GQ3\0?@M\+?&_B6XM+6.RM)]>\5^"-#
MU[6);6RA/E6EO+J-_<O!;1?NX(F2)/E1:_E3_:4_X*7_`/!8#Q;_`,%5?VB/
MV"_V&]2^%>LCP#JDEYX-\-^+/"7P]L[F+PWIG@;PEXBUJ2Z\5^+[K3K:YF@N
MM=E:&*YN_/F#I#"&V`#?).&L?GF,S#"4*^`PSRO#5\7C*^/Q#P^&IT,/6A0J
MS]LH37NRFI>\HKEOK?1X9IGN%RJA@J]6CC,0\?B*6%PU'"4/;5ZE:K2=6$5!
MS6KC&2LN;WK)76I_8SD?7Z<_RHSCG^AK^3+_`(23_@[!QG_A#?V=CGGBY_9T
MX[]_%/&.G)S_`$X;X!?\%7/^"L_[/O\`P4F_9^_8C_X*2>"/A>;3X_7OA73K
M2T\+Z3X036].TOXA:IKOA/P7XU\->)?AYK^H:#<V'_";:'=:9KFEZY:W%XVG
MV&J);0:?=M97;>O'@3'5J6*J8'.^&,SJ83"UL94PF7YS"OBY4,-#VE>5*BZ,
M>=P@I2?O17FCS_\`6["TZF'ABLJSW!0Q&(H86.(QF6U*.'C6Q$XTZ4:E7F?)
MSU'RWY-+W>FJ_L'HKYD_;0^)WBWX*_L<_M6_&;P'=6MCXZ^$W[-OQQ^)O@V\
MO[&'4K&T\6>!?AEXG\4>'KB]TVZ'D7UG!K&EV<ES8SCRKF%'@E`#M7\BW['?
M[?\`_P`''W[=_P`,M9^+O[-%G\#?&W@3P_XUU+X>:IJNI:#\#_!\]OXKTG0?
M#?B2^L$TSQ;X@T;4;B*'2/%FB7`OH+62RD:Y>!+AKBVN8XO-R3A;&9W@<7F5
M/'Y1E^"P>(H8:M7S;'?4:;JXF$JE"$).G.+<HPEHY*5]$M+G9FG$.&RK&8;`
M3PF98W%8JA4Q%*CE^%^M35*C*,*DI)5*;LG+=1M%:RLC^X+<OK^AI<_7_P"O
MTQ_GC],_R5#Q1_P=CY`_X0/]GS.?^?W]F?\`4?\`":_RY_&OV^_X)GZA_P`%
M#=1^"/C&;_@I7I'A'1OC@GQ7UF/PC:^"7\"2:._PH'@_P2VC3S/\/M6U;1SJ
M,GB]O'*2BZG74UMH[7SHEM&L9))S3AMY7A/K;S[AO,%[2G3^KY7FD<9BG[2Z
MYU2C3C^[BU[\K^ZM;#R_//K]=8=93G>#;A*?ML?E\L/02BH/E=5SLIRYGRQM
M[SMKN?HQ_GI17\>/[<7_``4^_P""K=G_`,%@?BK_`,$[/V(-6^&&H/')X,7X
M7^%/%G@WP)'<R[OV8?"'QR\9C4/&7BVYLK7Y3)XLU"V-_>19C2UTNT5Y1;1/
MW_\`PDG_``=@@?\`(F?L[GW^T_LZY."?^IIS^GOW%>FN!<;'"Y?B<5GG"^7+
M,L#ALQPM',,W6%Q,\)BX\U"<J4Z%TW:4)M7@JD9*,FDCA_UNPTZ^*HX;*\\Q
MOU+%UL%B*N#RYUJ,<1AY*-:*J*LKI74E=)\LH-K4_K/SGU_(C^=)G_/_`-?I
M_GTK^27]A/\`X*I_\%0=#_X*C>#?^"<__!0[P=\,_P"V/'MEK(FE\,Z/X>T_
M6?"=U:_##7?BAX9UW1O$'@77-3\*>)=`UVPT)M*U"QGB>_L[B_\`-%[IU[HU
M_H]Y_0S^W]\8?''[/_[%'[3_`,;OAI?66G>/_A7\$_'_`(Y\(WNI:=;ZMI]O
MKWA[P]>:EILMYIEV#;7MNMQ#'YMO,I25,J<9S7EYIPOF659EEV65JF!KU,VI
M8*ME^)P>)^L8/$4L?6^KX>I&M&$6H.JG"=X-JS:NK'HY?G^"S'`X['488FE#
M+JF)HXNCB:#HXFC5PM/VE:G*DYRU4=5:6M[7/L*BOR$_X(B?MA?&W]N/]AC1
MOCQ^T#J^BZW\0K[XG_$/PM->^'_#VG^&=._LGPY=Z;#ID2Z7IBI:K+&ES+YD
MX7S921O9L+C]>Z\G,LOQ&4YAC<LQ;IO$X'$U<+7=*3G2=6C+DG[.3C!RAS)\
MK<4VM6EL>A@,;1S+!87,,.IJAC*%/$4O:149J%6*G%2CS2LTFKZO_(HHKAOB
M;\1O!WP@^'GC?XJ?$/6[?PWX$^'7A77_`!KXPUZZ65X-(\->&=,N=8UG4'B@
M26XG^R6%I/,MO;137-PR"&WAFF=(VY(0G4G"G3C*=2I.-.$()RE.<Y*,8QBM
M6W)I)+<Z9SC3A*<Y*$(1E.<I.T8QBFY2D^B23;?9'<T5_%?^R/\`\'`_[7?B
M+]KWX.^+?VJ_#/A_X=_\$_/VL?B?\5OA[\&M=U/PQI6BCPBFD^(M.TC0+Z?X
MB"6P_P"$DM/AQK.O^#_"OQ-\0ZFMAH%M:ZWKGB`V\,ND+8VG]IRL'&001G@@
M@@C\._8BO=S_`(:S/ANMAJ&8QH/ZU0=:E5PU95Z+E3J.CB,/*I&,8QQ.%K1=
M/$TM72F[/N_(R;/,#GE*M5P4JC6'J^RJ1JTW2J)2A"I1K*#;;H8FE-5,/5T5
M6&L=G920.IHR.#ZX_6OAO_@I3\<_B%^S1^PK^TQ\>OA3?6.F_$3X6_#B]\4>
M$[W5-+M=:TVWU6WOM.MT>\TJ]#6U]!Y5S+NAE4J6VL,%>?QL_P""+'_!>NS_
M`&S-3M/V:_VN[GP[X)_:;O)II?AUXML[2+PUX.^-EE<2S7,.@V.FY^Q>'_'V
MEP%H[?2X9?L'BW38%N='$>KP7.ER/!<+YOF.28[/\%1CB,#EV(^KXN-.7-B:
M5J5.O.M[!0<I8>G"I'VM12;IKGJ./LX2DEB<_P`NP>;87)L35E2Q6,H.OAY3
MBE0J?O/91H^UYK0K3DFH1E&TVN6+YG&+_IXHII.5R.00>0W8]""#W]0<^E?@
M7\&OV_OVD?&?_!>+]IO]@77O$'AV?]G3X6_""Q\:>$=$@\*Z5;>([?6[CX?_
M``%\0R27WBF./^T[^W_M+X@^(W6WE8((IK6/[MLN[DRS)\7FU/,ZF%]ERY3E
MM;-,5[6;@WA:$Z<)^RM&2G4O5CRQ;BGK[R:.K'9EA\OJ8"G751O,<;3P&'=.
M"E'V]2$ZD74;E%Q@HTY7DN:S<?==]/WU)`ZT;A[_`)'_`"/QQ4%TQ2"1E9E(
M7@@\C\\CMWZ\CO7\)_[%G_!4#_@X2_X*!6_Q%N?V66^"?CR+X4R>%(/&YU3P
MI\&O!1TM_&B>(7\/>2/%^LZ(=2%ZOA76VE;3UN!:M:HMSY1N+?S?0R+A?&9]
MALQQM'&Y5@,)E3PBQF(S7&?4Z47CI5H8=1J.G..LZ$XOF<?>E3C&[D<>;9]A
MLHKX+#5<-F&+Q&8?6'AJ&`PWUFI-854I5KQ4XM<L:D7L].9Z)7/[MP0?P^H_
MG1G_`#U_E7\CE[\2_P#@[!\*(^MW/P5^!7C*UT^)[FZT.QE_9TNI+F.-"YC%
MMIOQ/T#5[MV53LM])NS?S$F.WCDDVJ?K'_@EK_P7`\6_M0?'76_V*OVVO@LO
M[-7[7>CPZF=%TFUTKQ+X;\/^-[_1;";7=9\*R^#O&EQ>>*?`OC.P\-1KXCTZ
MTOM9\0Z3XMT.'5=1L=1T:>VTS3-<[,7P3FE'!8C,,'CLDSK#X.'M<8LDS2EC
MJV%HW477K8?DIUE1BW>=2$91A&\V^1-KDPW%6!JXNA@\3A,URRMBI>SPSS3+
MZN$I8BK;2E2Q#<J3JS>D(-IR::6MC^C+/7V_^L?ZTM?C3_P4$_;W^-7[//CM
M_"GPGTWX;Z5X=\')X+?XA^+/B!IOQ&\1WDC^-_AG^TK\63>Z=HWPQ\'>.]?T
M'PKX"\(_LSZK<>(/$-QX,\3:9XJN_&@L)=8^&.F_#OQ;XMN/N_\`9+^-_B[X
MT>`_$T7Q(\.V_AOXI?"OQ[?_``O^)-EIMC-IVAW7B"V\,^%/'&DZQHVGW&N>
M)I=)35_!7CKPG?Z]X7/B?Q8O@7QC<>)/`47C3QO%X73QAKG@5LJQE#`T<PJ1
MI^PK\CARU%*I&-11<)S27+RS4HM<LG*'/!5$I2Y5[5/'X>KBJF$@VZE*_,[>
MZW&_,E*]DXN,E9J[<)K>+2^IZ***\T[3SWXL^&?$WC3X7_$7P?X*\4MX&\8^
M*O`OBSPYX3\;)9'49/!OB36]"O=,T/Q7'IXFMOMTGAW4[FUU>.S-S;BZ>S6`
MS1ARXP_@9\#?AG^SG\,?"WPC^$OART\,^#/"6G06-G:6ZQ_:]0N5C07FN:Y>
M1I')J_B#5YE-YJ^KW6ZYO[N1Y93\J*G>^+(-=N/"_B.V\+7,-EXEN-!U>#P]
M>3JCP6>N2V%PFDW<L<L-Q"\5O?M!+(LMO/&R*RO%(C,I\\^%7QJ\)_$ZQCAM
M[VWTWQ9!!OU?PK=N;?4;5HA$)KNQ@N5AN-0T>1I898;^*+=`MU!:ZK%IVK"Y
MT^WV5>LJ$L,JDE0E5C6G23:C.I"+C"<DG:4H)RY&T^3FERV<FW/)#G53E7/&
M/+%_RQ=KV[7LKVM>VI[)11D45BDEL4%?CY_P5&_9G^./[0.L_".Y^$'@2X\9
M0>&=(\7P:Y)#KGA?1Q8S:G>Z!)91E?$.N:3)<&>.RN6!M4F6/RB)BFY-W[!T
M4`?QD>-?^"?'[9^@VTEU>?L^>-KR*-7=D\/OH?BNY(QMQ':>%M7UFZE;C.V*
M%V(P1G/'QC\1/@-\<?AY';:IX_\`@U\5O`VF37$:1:AXQ^'GB[PS9R,K]$NM
M:T>Q@8X.<!SD$$<5_H"$`]:0HASD=01GOANHSUY_Q]30!_%=^S#XI\3^"-?T
M/Q1X/UK4?#WB'2I(Y;+5--D\N:(G$4L4T;!H+NTN$=K6]L+R.>QO[::6ROK>
MXMIY87_JT_9I_:'L?C9X;2VU:.VTKQ[I-C;3:SI4+!+;5+0B.)O$.AQNYD;3
MGG>)+ZR#3SZ#<75I;7<]Q;W^EW^H;_C_`/9:^`/Q+EGO/%'PM\*G6)Y1._B+
M1-/C\->)9)P#MFN=>\/_`-FZG?B-V,GV;4+B[LI7'^D6TR%E;YG/P`U[]FO6
M=.\>>"-2U7Q5X0T&>&?4(IQ;?\)/I^DQVJPZI'JWD"QTG5-.U&V6\BNM8MK7
M3DT&:_MM0GT=--TV^UJQ`/T8K^,'_@KY_P`K'W_!+`?]0;]C\_E^UI\8?\FO
M[-[>X@NH(KFUFCGMYXDF@GA=98IH95#Q2Q21DI)'(A#HZ$JRD%3@U_$S_P`%
M_O%<W[-?_!9?_@G?^V)X_P#"OBR\^"OP]\&?!+5+[6/#FEV]Y=ZY>_!S]H3X
MB>.O''AKP[_:>HZ/I%YXDL?#OBKPY=0Z=>ZOID;_`-KV3S7-O`99A^@>&L)5
M>(,5AZ?O5L3D.?8>A27Q5JU3`25.E!/24Y.ZC&]VVOE\9QU+V>486M)\M*AG
M645J\_LTZ-/&TI5*D[7M&,5=NVFY_;;@>GK^OUYKQ?XR_L[_```_:&T_1M'^
M/GP8^%GQGTKPY>W&J:#I?Q3\"^&/'=AHM_=0K:W>H:79>)].U*"PNY[?%O/=
MVL<4[PD1/(8PJC^>L?\`!V%_P3KZ?\*F_;#/N?AU\'1G\OCX`<=,CTK\H_\`
M@J=_P7CC_;I\/_`;X8?\$X-;_;9^"GQ9A^)-U%K<?AV\;X9Z_P#$&V\2Z=#H
M?AKPEI+?!GXL^)M>\4W\NOSPFST.\LEMWN9XVM!-<L4-93X=\95LPP\*F`QV
M24OWDIYK7C4I4<&H4I3<YU*,_:1C**<&XZ>][S23N9AQKPS#!UG3QF%S2:4(
MPP%!QJU<2Y5*45"$9Q<9-<RG[VW*Y;VO_>7!:VEA80V5C!#;65I:16MG;6Z)
M';V]K!$(;>""-`$CABC18XHT`1%4*@`''\9G_!HI_P`?_P#P49_["W[,/_HW
M]I.O['?#=IJ%EX5T*PU.X>[U.TT'2[6_NGE>>6YU""PABO+B265WDE>>Y265
MY)&+N[,SLS,37^>I_P`$=O\`@I+\(?\`@C9\3?VZ/AG^UQ\-?CF_C/QGXU^'
M'A>/0?A]X4\(ZE?^'-9^#NJ_&/3O%5KXF@\8^/\`P,]FTTWC32CI#:?_`&K'
M>PQWD[O;Q):R771PC@,7F?"W'N5Y=2GCL?B)<-U*&'HV=:O3P^8XF5:K&$I*
M4U"+C*;C>RE%O<YN),5A\#Q!P=C\94CA<)1>=*K7JMJG2E5P%&-.$Y)/E<GI
M&Z2DT[:W/]$ZOXPM9_Y7`?"G_8&E_P#7<7B&OL'_`(BPO^"=1_YI-^V$/I\.
MO@Z?_>^U^7?[%?[1/A__`(*'?\'+?@S]KOX"^"?B1:_"E?"GB76==/C/0=)T
M_7?"&B^'_P!CG7O@PVK>*X?#OB#Q5HNF66J^/;O2=&T>6/7+LW<^M:7&\,%Q
M-+!#Z7"_#&?Y#2XKQV<95B\NPD^"\_PT:^)I^SIRQ%:E0=*BFWK4J*,N2*W:
M:WLGP\0YYE&<RX?PF5YAA\;B7Q-E%?V-"3G-4:<Y>TJ-)64:=TYMM<J:;TU/
M[`O^"@8S^P7^VM_V:3^T6/S^$'B^OXM_@;^P/\1_B;_P1T_93_X*&_LB7&M^
M'_VT/V+_`!C\:/%6DW7A9(+G5_'?PO\`#'QH\:^)[W1+?1[BVNH]?\1>";VY
MU7Q%X?T(Q36_BW0-3\<^!;[0O%M[XB\.:?8?VD?\%`SC]@S]M<'`_P",2OVC
M#CGM\(/&&.><\#ZYQ7YI_P#!MB5?_@DS\$5(!QXV^-N5)P>/BWXL`++P1SD<
MCD@CUKRN'LXQ.2<(X[,<*XRE1XKRB-6C4?[K$X:IE&;4L3A*\4[RI8BDZE*I
M&SY5*^DTK>EG.6T<TXDP.#K\T85.'LS=.M#2=#$0S#*IX?$T9KX*M*HH5*<M
M&W&VUT<=/_P7M^"LW_!)^Y_;I@?2HOC9Y;?!Z/X*1B>>>W_:HGTAGM?#K63W
M\=]/\/`F?B2=674C=2?#2&:V2Y;QK$^A5_-?^WM_P3^\9?LW?\$E_!/[6?[2
MWVS6OVS/VTOVWO`/Q,^)^JZ]9B'Q#X-\*>)OA!^T=XMTOP3>I<117%AXDUO5
M+]_&GQ$MH[;2A#KMWI/A2ZTUF\"6E_=_T)Z3_P`&[OP@TO\`X*D3?M=K=^%9
M/V3HKR+XS:;^SL@U:VEM?VC(KPO;6,VCV]G'X=G^#VEZLTOQ'T[35UR$_P!O
MS1_#NY\(S?#NVGBU'D?^#L90O_!/#X)JNU0O[9WP]VKD#@?!#]HKHN>F6[9/
M.<]:^FX;S7(L#Q)D.6\*SJNAGF;4,RS2K5@U5PM"U2IAL@C)<KE3PE7FJ8BI
M&ZQ#]A&[5&1X>=Y?FV,R+-L=Q!&'MLJRS$8+`4Z+4J6)K-0IXC..5.2C6Q4%
M&G1I7O1BZKY5[5)?O7^Q5Q^QO^R7[_LT?`G_`-5;X6-?Q!?'#XQ_M9_`O_@X
M@_:\\>_L6?!/2OC]\<;>ZU/2K#X>ZQH?B#Q!9W'AS4_A5\.8]?U=M.\,^)?"
MFJ/+I4*031RKJZ00EM\]O<+M6O[?/V*_^3-_V2\]OV:/@0,=]W_"K?"PV\=\
M\'KSD$<5_%/\1?VV?A/_`,$_O^#CC]KG]HGXT:/X\USP1I[:UX5FL/AQI&A:
MYXG;4?$WPI^'=K830V/B+Q/X2TW[)%):2FZEDU=9D3:T-M<!A7F^'\:D\VXW
MA3P4,RK/A[.%3R^HJDHXVH\9A4L-)4I0J256=XM4YQDKO5).W9QDXPP/"LZF
M,E@*<<\P,IXZ#@I85+!UKUHN<)PO"Z>L);[=#]"!_P`%//\`@X_/_.*KP%_X
M:OXQ'//0$?'@8],_I7PC\'O'WQZ_;4_X+M_LI^*_^"H&A:1^QE\9_A=X8\#R
M?"3X66_PV\?>%[;XI2>"O$'CKQW\.]#TO5/%7B'Q3:VC:]XNUCQ)//XFO=;;
M1M<F\/R?#_1K4>*I$BC_`%H'_!U[_P`$X.A^%W[8?MCX;_"+';_JO6?7'4],
M#M7XY?$7]KO1_P#@L%_P71_X)_\`Q7_9/^%OQ4A\)?!G5?@'#XG_`.$XT;1=
M.U^T\-?"CXW>(_BYX[\:ZU#X7\0^+=&T7PYINAZZ=,T^>^UUI+_5(8K2.**[
MUJQL9?I,EP&9THYU/%\#X/A&B^'\WB\[P]/%TIX:3P=22I7QN)Q%!QQ+_=27
MLW+W[TY0E:4?#S'%8*I++5AN*L3Q+66<99*.4U51E&K_`+53O5_V6A0JJ5"_
MMH^_[/FC^]A.-T_[)/\`@I2,?\$Y?V]U[#]BO]J+WZ?!#QOCGG/N>_6OX@_^
M".?[;?\`P51_9K_9B\:>!?V'?V'K#]I?X4:I\;_$OBKQ!X[N?A_\3O%DNF?$
M&^\!_#;2=5\)B_\`!?C'P_I<":?X>T3PMJHL[BS>^0ZYYLMT\,T$4/\`;Q_P
M4G./^"<G[>YX`'[%7[4>1P-I/P0\<':`"R\'Y54%N?EK^-?_`((??\%M?V3/
M^";G[*'CSX'?'?P9\>_$/B_Q1\?_`!5\4K&]^%_A+P'K_A^/P]K7P[^%OA2U
MM;J\\3?$WP9?1ZNFI>"M7DN+:'2Y[1;.6PECOI9II[>V^?X&I5Z_!?$-/"\/
MT^)*O]M91*.65HUY0E!8;$?O;8:M1JWHIIJ/-9W5XR5D>QQ75HT.*LEJ5\WJ
M9)3_`+)S"+Q]/V7-S>WI*%&]6E6@O:N]GR<UHW4D?T??\$P/VU/^"HW[2GQC
M\=>$OVY_V)[/]F7X=:)\.)]?\*>+;7P!\3/"3Z[XS7Q+H.G1^'GO?&WBWQ#8
M7"'1;[5=1%O:VUO=[K+S1/Y,<L3_`+CD8![\'TX_2OYCO^(KW_@F_P!?^%6_
MMA\#C/PW^$1Q^!^/7^>W6OV!_P""?7_!0WX)_P#!2;X0>*OC7\!]!^)7AWPE
MX1^)&J?"W4[+XI:)X:T#7Y?$6E>%_"?BRYNK.S\,>+O&=C)I#Z;XQTN*WN9M
M4M[M[R+4(GL$BAM[BX^0XER#.Z$ZF:XKA6?#N7OZO2]G2I5XX2E448TE+VF(
MJU:G-6G[SO+EYI-15M#Z7(\YRBLJ>78;/H9QC4JE3VDY4UB:T%S3;E"E"G32
MI1?+[L5HHM]U_'5^VO\`M6^$/V(?^#G;XH?M0^//"_BWQGX3^&$_@W^UO#?@
M:#3+GQ3J(\:?\$__``?\/++^RX-9U'2=-D-GJ/BVTOKS[5J%L%L+:Z>(RSK%
M!+^KD_\`P=E?L9VQ2.X_9I_:L@DD&Z-)M)^%4+."<?*'^)BELGY?ESSQSV^2
MI`/^(PZ4G@&8$YQ@C_AU]#ZDYPWH/E*D\%21_1!_P5)_X)C?"3_@I7\`[OP%
MXG2Q\+?%WPA#J&K?!'XN1V?G:IX&\2SQ(T^FZ@T""\U3P/XH:WMK'Q7X>9Y(
MI8HK/6["&+Q#H6AWEM]YG&*X1B^!,+Q+E.+Q$*G!V1*MF>%S*K06$H26)A&,
M\%3H2]JJ52,ZDYJLJGLJL_W;Y8QG\AE6'XCE3XJKY'F&'HSI\39M*&`Q&`I5
M?;58SH<\EBYU4X.I"T:<73=)SI6E)*?,OYC?V._CMXF_X*;_`/!P[\,_VS/A
M'\$_B3X6^#G@7PW?KXHOO%.G1SR>$=#T;X`>,_!&GZGXPU+2&N_#^DWOB3QC
MK4&F:+I=OJE]+=)/!)')*8[YK7^J#_@K3_RC-_;G_P"S8_BYG_PC]1K\3_\`
M@E-_P5C^+'P&^,DW_!+'_@J:U_X-^//@+68/`GPF^-WC+4&EA\=QGRU\+^#O
M'GB>^D2'5KW6[.>SF^&'Q1:1K+XAZ;=Z;I&L7'_"6M::GXM_:_\`X*T,A_X)
MF_MSMN&T_LR?%SYL@@@^$-2^88Z@^H.,=*\?B.6)7&?">&G@*>!R_+_[!P.3
M5*&)GC\-CLLH9C3KT<71QLJ-+VRJ*LU/FA&=.2C3J-SO*7K9$J/^K?$&(CBJ
MN*QN,EFF*S2-?#QPM?#9A/!\E?"U,+!R5%TW3LDW:22E%^]8_/3_`(-A_P#E
M%IX:_P"RY?&'_P!.&C5_0]7\&'_!'+_@O%^R#_P3Y_8OTC]G;XS>`OVAO$7C
M:P^(_CWQ?/J7PX\(?#O6O#)T[Q1=6$UA#%>^(_BMX/U-KR%;20743Z,L,;,@
MBN;@$L/U3_XBPO\`@G8>!\)?VPLG@?\`%NO@\W)Z<#X_`GZ`@GH#2XLX(XMQ
MW$^?8O"9!F-?#8G-<96H5J=&\*M*=>3A.#OJI)IKK9[;!PWQ5P[A.'\FPN)S
M?!T<10R[#4ZU*=1J=.I"E"$H2C:ZDFMK:]+O0_I[)Q_^O%?RU_\`!PM^T5X]
M^+OB']G7_@D9^SK?>9\6OVN/&O@_5/BA+;,SV^B?#"+Q"4\,:5X@>'3[VXL]
M%U3Q/H>I>/O%&H:9=6>H:1X2^%TRZA;W>A^)ITD_:OX6?\%!?@3\5_V%?^'A
M%J?%/@CX#KX!^(OQ%N4\?:9I&G^+[#0_AKKOBCP[K$%QHV@>(/$>GW&KZEJ?
MA2]M_#VDZ7KFHW>L27VDV<"?VE>BQ3^2#]AW_@E_KO\`P7=\7?M0_P#!1']J
M[XD?$OX2Z/\`$CXQ7&C?".P\")H/VF[T7P_9/I]SI$%UXET"]BO/!OP[\/KX
M-^&WAG4[&);C5-1\->)UUB:75-/N7DX>"<LPV7X[,.(.()O+\%PW-X>$JU">
M(OQ!5<Z6!I?5J;4\1]4J1GBJU.$KQ=&#DXQYF=/%.85\;A,'E&2Q^N8G.HJM
M)4JRH)913Y)XJI*NXOV7UB$H8:E+5MUG:+:/W8_X*/?\$EOAY\3_`/@DWI7[
M(WP&\/Q3>,OV4O!VE>+OV=MBZ='KWB3Q?X*T^Z?Q1INHS6-MIUO?^)/C5IE[
MXK36'V:=I.H?$CQ!I7BG4XHAIL1B[;_@@O\`\%!?^&Z?V)_#VG>-M>EU?X__
M`+/3:9\*OC`VH7'GZSKUK;63GX>?$F^>:[NM0O#XY\-636VJZSJ'D3:KX[\,
M^.7CMX[6"VEG^`3_`,&FO[*/)_X:H_:<SUS_`,6UX/K_`,B>V/\`ODY]#T/Y
MZZ?\--2_X-O_`/@JQ\%+H^-/%?C#]B?]J'P=;^#?%GC;Q4+:&^BT6?5=.TOQ
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M`+(>,$"'XW`\>G[1WQ?/Y\]_IU&*\7)\UQV2\"?VAE]:6'Q6'XXH\KY5*,T\
MBJ0JT:M.7\2E52E"I3FO>BU:[L>CF>7X7-.,%@\92]IAZW"M;3:4)+-*$X5:
M<_BIU:;7-3FK34DK:-GQ]_P1_P#^"POC3QGXRN/^"=__``44MKSX8?MJ?#/4
MG\#:%XA\:K;Z+)\7[K25A@3P]KDF\:;'\4(;+R[K3[^RGDT?XIZ0]IK_`(>N
M+K5+L?VUXY^S=S_P=9?MOGU_9RTEA]&^$7[)Y!^A!!!]".O6OT*_X+`?\$=_
M`W_!0_P3'\3/AC-I?PO_`&R/AQ8K>?#3XIP>;I47BV/23)?:?X$^(.H:9#)J
M$FG_`&P++X5\511W&M^`]68WFG?:-*N]8T;5/P'_`."'7BC]I#Q9_P`%SOC-
M>_M=Z/J^A?M'Z+^R]KG@7XI6GB.S>PU^ZUGX::9\`OAUI^M:OYMS=Q:MJOB7
M0/"VD>(K_P`1:;<SZ/XJN=3F\3:(W]D:K9A?I,J61YCE'&/$&3NGE]?$<*9C
MALVR%R:^J8VI6PM58K+[OW\NQ,:=1J&^&JVHJ\7!+Q\?+-<'F7#.3YGSXRG0
MXAP=;+LX4;?6<*J.(I_5\>KODQU!2IJ][5XKG4;QFS^["[_X]Y/I7\8__!H$
M/^)-^W[_`-A/]F+_`-)OC[Q^8'X<5_9O><6\ISC"D_D,_GZ>M?YP?_!"#_@K
M5^SC_P`$P;#]I^T^/?A/XQ^*9/C3=_!NX\+-\)_#O@W7TL4^'\/Q/CUE==_X
M2WQ_X&>T:Y;QII9T[[#_`&F)Q!?>>;,Q0"Y^>X0R[&YKP;QW@,NPU3&8RM6X
M7E2P]%*56:I8_%U*CC%M/W8)MM=#V>),;A<NXGX2QF-Q%/#86E3SV-6M5?+3
MBZF%PL*:;L_BFTH^9_I"[1S[]?\`/Z_7FOXQ_P#@O[I6F_"/_@K!_P`$M/CW
M\/K=;?XI:YXL\%6>NPZ5_HE[K-M\-_C1X*F\+_VB;<)+>/K%OXS\0>&[F29Y
M)+O1[*'2Y0UE;Q1+]0^(?^#LO]@VUTJ]E\+?`[]K+7-=2!FTS3=7\*?"+P]I
M=W=#)2"_UJV^,_B*\T^W?&U[JU\/ZM+$""EG.WRCXI_95^$7[9/_``6S_P""
MF7PF_P""AW[1'P:UGX"?LG?`"\\*>(/A=I.L6NJ6=CKUK\.O$%UXO\!>$?!=
M_KFDZ7>_$.?5_'MU)XA\?>/K71+/PQ+ING7_`(<MY]/O(]"T>+NX3X=S?A7&
MXS/N(\++)\LPV59G1J1QLZ5.IF-7%X2KAZ.!H8?GE.O*K4J1E).#@E%.3ORI
M\G$6<Y=Q#A</D^18A9EF%?,,OJPEA(59PP5/#XFG6J8NK7Y%2I*E3A)1;G&3
MYK1T;3_K:^*_[*/PB^,7C'1/B/XCT[5M)^(>A:--X;MO&GA?5&TK6+SPY-9>
M)M,_L36[>6*]T/7[2STKQQX^TK0;G6M(O]4\*:9\0_B)9>$]0T.'Q[XO76?2
M/A%\(/A[\"O`&A?#'X7Z`GAOP;X>_M"2PT[[;J.J74MYJ^IWFMZSJNJ:QK%W
MJ&LZUK6M:UJ%_J^LZSJ]_>ZGJFI7MU>7MU--,S'TI>@YS@#GU^4<_CUIU?ED
ML5B)T(8>5>K+#PY7"C*<G"/+S<GNMVO!3GRW7N\\^6W-*_Z#'#T85)58TH1J
MS^.:C:4M4W=[ZN,7)=7&/-=Q5BBBBL#4#R#V]_2OR"_;=^$VN>`-5D^)WA.V
MO8/#FIZLFJ3:KI4\\=UX0\87-VLPG>>`)=:9::G?N+G1]1AN#%;ZQ<W.E+_9
MV=$@U#]?:SM6TG3==TS4-&UBQM-3TK5;*YT[4M-O[:&\L;^PO87M[NSO+6X2
M2&XM;JWDD@N()5:.6)W1U*L:`/YAT_X*;_M3_!2**R_M_0_B3H]A!#:P6/Q(
MTB75+^."`'+/XET:^T'Q/J%Y*/\`67VO:QK4[L%>0S8VMZMX-_X+X23K!:^-
M_P!FM/M$9*7NI^%?B65A=E)4O;:)J_@UI$&<GRI/$$AP%!F/..P_;8_X)2^+
MM034?%W[,SKXBLY$N+BZ^&&N:I':ZY9223!O+\)^(-4N(M/U:Q6)VQI_B*]L
M=5M(K-?)U?7[B]6WMOYS?$?@;QG\./%.I>%/B!X3\1^"?$]A,3>>'_%>BZCX
M?UFWCE/FV\TFG:K;VMU]GNH62>UN!$8+J!TGMY)()(Y'`/ZH=(_X+:?LU7T,
M;WWPW^.EI<,JF2"ST3X?WT*N5^98IY?B-I\DB!OD1WM8M^-Y6/YEK[;_`&6O
MVSOAA^UP?&H^''A[Q_H8\"#P\VK-XWTOPWIPN1XE_MO[!_9O_"/^*_$WF&/^
MP;S[4+P63*)+=H!<*TIA_BQT7K']8_\`'^7/TK^A_P#X(DD;/VC>1RGPEQSU
MPWQ)Z4`?O1129'J/S]L_R(/T.:,CU'KU],Y_D?R/H:+KOOMY@+44P1HRLH5H
MV^5U<*496^4JP<,K!LX*E6#9P0037GWQ#^+OPQ^$^F+J_P`1_'7A?P;9S"Y^
MQC7]8LM/O-6EL[66]N+/0M.FE&H:]J26<,MR-,T>VO=0DBC8Q6SG`;\-OVJ/
M^"DWBW]I7QCX:_8S_8=B\0:1XA^-WB*V^'^L_'J^TV\T[5/#7A#5H91XP\0?
M#WPT\UCK-G)HGAU+WQ!J'C#6IM"U[P]I.B:RF@^'HM:NM(\4:+Z^5Y'F.;5&
ML/1E##TTZF)QM9.GA<-1@N:K5JU96C[D/>4(\U2>T(2>ASU\32H1O)\TF[0I
MQ^.I)VM&*^:OV\]C]Z_!R^&D\)>&(_!EW87_`(03P_HR^%;[2]2&LZ;>>'%T
M^!-#NM/U87%Y_:=E/IBVTEIJ/VNZ-];M'<FXG,IE>SKOAKPYXHL7TOQ-H&B>
M(M-D(,FG:[I5CJ]BY`(!>TU""XMV(!(!,9."1WIGA;PYHW@_PWH/A/PY80Z5
MX?\`#.C:9X?T/2[==MOIND:/9PZ?IMA;C`Q!9V5O!;1+V2)17PG_`,%*?VB/
M'G[-'P(\'^-OA[X\\`?"W5/%/[0GP"^$VM?$OXH:/!KO@?X>^#_BC\1M(\(^
M*_'&O:;=^)O!ME-9^%-%O[O7)GO_`!-HUA#!8RR7>HV4(>YAXL'AZN+QV'PF
M$FU5Q%94J%2;G!J3^&4_9J<T^5-M04F[.,5*ZNL77IX;"UL1B(\U.E2=2I!*
M+NHQYG%<[C!]DYN,=FVCZO\`^%`_`G.?^%+?";_PW7@\#ZX&C=:W-!^%'PM\
M*WHU+PQ\-O`/AS41&T0U#0?!WAW1[X1.-KQB[T_3K><(XX91)M8<$$5^17P!
M_;G^)^J_MC_!G]F?2/VG_P!E/_@H-X&^*O@7XQ^+/B!\0/V7?!O_``B^O?LS
M2?#FP\)WGA'5_BA>>%/CO\=O!5_X5^(VHZS=^#-&L[VW\!ZW!XAGTJZM[_5[
M<3V5S^V$A(CD(R,(Y'X*<$]\]^N:ZLPH9A@)4:.)Q%2:Q%!5Z=JF(494G.=)
M-TL1"C6I^_3FE"K2A)Q4:B3IU*<YXX2KA,7&<J5"$71J^RJ)PHRY:BA3J+EJ
MT74I5/<G!\U*I-1E>,FIQ:'@``*``!P````/0`<5POB+X7?#3Q?>KJ/BWX>>
M!_%-^BB-+WQ'X3T'6[M(P`/+2XU/3[J94P%&P.%X7CY17YL?LP_\%2/V8O$7
MPRUF3]IG]KS]DSX8?&3P_P#&O]I3P%XA\"^*OC?\+_AUX@T70?AO^T3\4O`'
MP\_M;PAXH\:6^N:9>:G\.O#7A35Y;B[@A36&U#^VK**.QU"UB7U7_@G+^U?X
M@_:_\"?M'^/M4U[P1XJ\,^!OVU?VE/@W\)O%'P]>UN_#/B3X-?#SQ396GPU\
M06NL6.JZQIOB0ZUX<O;;41XFTJ[&F:];W%MJ%C#';31@NOE>99?]9JU*=;#K
M!U(T*E5*K2C*4ZGLX^RJ<L55C)PNG%VY5%[/2*68X#&_5H0G3KO%4Y5J=/\`
M=U)05-1;]M"\O9R2J*R:_F5]&?6?_"@O@4/^:+?";O\`\TY\']_7_B3<^@KL
M_#?@KP=X-MY+3PAX3\->%;69_,GMO#>@Z5H=O,^<[Y8=,M+:.1\G.YE+<GFN
M@N9X[:":XF=(X8(WEFD=@B1QHI9I'9OE1$`W,QP`H+9XP?QN_9V_X*"_&#X@
M?M!>#O$/Q-\.^$/#G[$_[8GB7Q]X'_84\;P6FOZ?XLNO$'PHMO-TB3XG7FK0
M6VEPP?M5^'="^(OQ/^!-O';Z=,GA;PAI&A2_VKK?B[3]ZPV&S',:.+J0JSJ4
M<+352K&K7E^\:C.JZ=&$F_;5HT:57$>S7O>RHU'&\E",[K5\%@JM"$Z<83K2
MY8RIT5^[C*=.GSU)QBE3INK4HTN9M)U*D$[1YI1_8V_L+'5+*\TW4K.TU#3M
M0M9[*_L+ZVAN[*]LKJ)H+FTN[6X22"YMKB!WAG@FC>*6)V21&5B#G^'_``UX
M<\)Z;%HWA;0-$\-:1`\LD.E:!I5AHVFQ23RO-/)%8Z;;VUK&\TTDDLK)$&DD
M=Y'+.S$[*'*YSGZ'(Y`X!K\E?VYOVJ/B#\(_VH/@1\%]'_:O_9W_`&/?`?Q"
M^"WQJ^(^N?$_]H;PGH/B71=3\4_#WQC\&/#GASP5H;^)?B[\(=*L]0U?3?B#
MXBU>5/[8U"^FA\/%[;39(8KNXM<<OP6(S&L\+AYQ@_95J\N=5Y4U##4IU)/V
M>'IUJDY*$9*"A2G/7EBKNSTQ>(HX2FL14ASOVE*C#D]GS\]>K"G%*=2=.$8\
MSBW*4XQLDVUT_6S`]*YSQ-X/\)>-;&'3/&7A;P[XMTVWNTO[?3_$VB:9KUC!
M?10W%M'>0VFJ6UU!'=QV]W=0)<)&LRPW-Q$'$<TBM^;_`/P3[_:Y^(_[1/Q`
M_::^&_B#X@_!+]H[P%\"-3^%=AX+_:Y_9P\-ZYX9^$OQ4U'QYX-O?$'BOP";
M*]\??%CPO<>/?A5=6NF2^)[SP'\3O%&AMI/C3PM#J6F>%-<CN=-NOKC]K[XF
M^)O@I^RE^TO\9/!9T_\`X3#X3?`'XP_$GPJ-5M9+[2SXC\#_``]\0^)M%74[
M**>VDO-.;4=,MEO;6.X@>>W,D23Q,P<54R_%8;,*>`;BL5.>%5.4)3BO]KC3
MGAY>_&%6DY0J0;A4A"K3=XSA&46B88O#U\'4Q5FZ$8UG4C*,9:4')55[KG3J
M)2A)1E"<X3M>,FFF?05I9VFGVMM86%K;V5E9V\-K:6=I!%;6MI:VT:Q6]O;6
M\*I#!!!$B10PQ(L<<:*B*%4`<#K'P<^$7B'4[O6M?^%GPXUS6+^037^K:QX(
M\,ZEJ5[*J)$LMY?7NF375S(L<:1J\\KL$14!"J`/AO\`X)\_MC>*?CA\$?&D
M'[2L_@KP1^T'\`+N*V^.L&FRP^'O"#>#_$WAVW^)7PH^,VE6^J:YJDNC>`OB
M-\)M7TCQ`EWJ^J0QZ;XBTOQQH4WV2;PQJ%O:>8?\$Z_VV?CI^UK\>?VDU\?Z
M%X<\,_`^;X;_``0^./[*NC6NA:II7CB3X*_%CQU^T)X+\*^*OB%<ZG=N9]2^
M).@_!C1?BCHNF6MA91^'_#_C?3]+G:>[BG$7:\ES3#/-Y\T:?]CJ'UNK"O95
M(UJU.%%X>4;.O&LJD*\''3V/[QM>ZI<ZS/`5WET4G-YBZBP\)TDW"5"G.I5]
MM%W]BZ?)*DU*[]K^[T=[?H__`,*!^!/_`$1;X3'Z_#GP><_^4:NU\.>"O!W@
MZ"2U\(^$_#7A:UE8/);>'-"TO0[>1QN^=X=,M;6-W^9OF92W)YYKHW*@$MP,
M=?3'3O\`R_'BOQF^./\`P4.^)W@?]H/Q?XR\&:5X/U3]@[]E+XC>`/@7^V)\
M0IXKB[\26/Q(^)\5[%XF\1^"]8LM9?2X/"/[*]QKWP:NOC?'>:+=7RVGC_QO
M;(]K?_#:^B/-@\-F.;2J4*-2I55.G[62K5Y^SD^>$*5*/,W&>(K5:E.GAZ7Q
M5*LX)-+FE';%5\'@%"K5I*/-/DC*E1BY)*/-.<N5)QITZ:G4J3>BA![R<4_V
M/U#3=/U:PO=*U6QL]2TS4K6XL=1TZ_MH;RQO[*\B>"[L[VTN4DM[JUNH))(;
MBWGCDAFAD>*1&1F4^8CX`_`H?\T6^$_3&/\`A7/@_P!`/^@-UP*]7BD62-'5
M@P=5=2.A5@&!!!((((^8<'J.*^)/VQ_VG/&7P4O_`(&?!_X+^$_#?CG]I+]J
M7QUXA^'GP7T/QMJ=YI'@#0(_!_@S5_B#\0_BE\0;S3F35[[P;\-/"&BSZQJ'
MA?P[+!XI\9:E<:3X7T*ZTV74I];TOFP4,77K1P^$J2A4GSRE:LZ-.$*4)5*U
M6K4O&,*=&E"=2I.;2C3C*3T3-L5/#TJ;K5X1G&#C!?NU5G*=6<:=.G3C9N4Z
MM2481C&[E*223;/H3_A07P)Z?\*6^$W3'_).?!WY_P#(&Z].?:NW\,^#?"/@
MJRFTWP;X6\.>$]/N;IKVXL/#6B:9H5G/>/%#`]W-:Z7;6L$MR\%O!"T[HTK1
M00QEBD:`?$EE\)O^"AOAS4_"WB.']KOX+_$B2/Q'H[^/OA[XJ_9DN?`O@35_
M"5UK^G#Q'!\/=<\*?%76_'G@?Q'I?AEM5NO#=WXOU;XL:;?ZY!86>LV5O9W5
MSJ-G]^#.WDY)Y/&,YY^[DD=>%R>,+P.!>,=2"C!9C''PFF[4JF+<8RBU[LX8
MJC0?,N;W91C*#Z3WLL/R2;?U.6&G&R3G"@G*,M7RRHSJ+?>+:=]T<E_PKWP#
M_P`)2?')\$>$3XU)R?%__"-Z-_PE&?[/&D9.O_8O[5)_LD#3,F[)_LX"RS]F
M`BKL,#TK\6OVG_VP_''@C]M3Q]\!;O\`;P_9-_8@\!>$?@!\$?B7X<N_VCO!
MWA'7M4^(_B;XC^,_CCH'BJV\.ZAXN^//P9ACLO"FG?#?PI+=VNG0:Y+#)XDC
MENY+-)[43_?'['OCC4OB%\+;[Q-??M6_`_\`;$@N/%FJ6VG?%;]G_P`.Z!X;
M\!VMI9V&DPR>%&MO#7Q4^+VEWFMZ7?\`VS4-1OD\3VTIBU>SM)-'M!:I<7G1
MC,KQ>&PV'Q6)K0E"KA\+5HT_9XURC0Q-*%?#Q5:>%CA%:C*,G"&(DXN\5%M7
M,<-CL/7KUJ%&'*Z=2M&I+FPZO5I5/9U7[.-5UG^\37M)4ES.SV=SW/Q'\+OA
MGXPOTU7Q;\._`WBG4X[5+*/4?$?A+0-;ODLXY)9H[1+O4]/NKA;9)IYI4@60
M1+)+*ZJ&D<MU.HZ/I.L:;=:-J^EZ=JNCWUM)9WVE:E96U]IMY:2H8I;6ZL;J
M*6UN+:2(F-X)HGB>,[&0KQ7S'^V-\8/&'P1^%7A/QAX&;3!K.L?M'_LF?"Z\
M_M:RDOK7_A&?C1^TS\*?A+XQ,4$5Q:LNI#PKXSU<Z/=&5DL=4%G>20744+VT
MWGO_``4A_:#\>_LM?L;_`!&^./PP&B'QKX4\1?!;3-*'B/3Y=5T@VWCSXX?#
MCX>ZX;JQ@O+"2:0:#XKU4V1%S&(;\6]PZS)$89,\/@<;C)9;3IRYGCL9+`X+
MGJR2A7C+"Q=WK[&'-B:+YHWT3=O=5ZJXK"T7C>>+OA,/'$XIQII\U*I&LX_]
M?)-8>HN5]DKZGTI_PH'X%'/_`!9;X3<G/_).O!_'T_XDW?O2_P#"@O@5V^"W
MPF'0\?#GP?P1W'_$FX->KH,(@YX11D\G@#KGO7Y"?\%(?B!^W+^S#\*/BG^T
MM\)OVCOA%:^!?#GB+X3Z3X=^$'BC]FB]\1ZO9V_C_P"(WP]^%M\U_P#$Z/XW
MZ3_:,EG?^*[[Q1;[/`MH##%!H7RX.KEX!8S,,50P<,Q>'JUY0I498FMC.256
MI.%.G3_V>E7E%R<E[TXQA%)WDMFL9/#8/#U,3+!^UITH3J35&EA^:,(0<Y3:
MJSI)I*/V7*5[/EM=K]4/^$`\"'PLO@<^"O"9\%*%5?"!\.:.?"ZJM^-455T#
M['_9(5=34:BJBTP+\"['^D#S*U=`\.Z!X5TNVT/PQH>D>'-$LS.;/1]!TRQT
M?2[0W5Q+=W'V;3].@MK2#S[J>>YF\J)?-GFEFDW22.Q\0^`W@C]I#P<_BD_M
M`_'KP-\;QJ7]BGPG_P`(7\"I_@J/#)M/[7_MW^TA-\5OB>/$C:Q]IT<6A0Z)
M_9/]EW19=1.IC^S_`"S_`(*-?'KQW^S%^QE\:/CG\,_[%_X3CP);>")M#'B&
MPEU31BVO_$GP=X5OQ>V$%Y82W"G2M=OO)"7<)CN?)E)98RC8QP];$8NG@:.)
MIXJ>(Q-.G3J0E7C0J5Z\HTU-_6*=*JFIS<9U)THRLF]8V;VE6IT</4Q52E*E
M"A1G4G%QINK"G2AS2BE"4HW48^[&,[/2S5S[;QGK7*>*/`G@CQQ%:0^-/!WA
M;Q?!822RV,/BCP_I.OPV<LZHDTEK'JUI=I;R3)'&LKPA&D5$5RP50.H7=M7/
M7C.?Z8[_`-<U^>OQW_:%^.GB3]IO1?V,/V6H?`WA;QY:_""/XZ_&;X[_`!2\
M-ZQX\\(?"/X?^(/$7B#P/\/-$\+?#;P[XJ\#7GC_`.)?C_Q5X9\37%O;:SXX
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MQG^TA\,OC?\`!S4;;4(?'&B>(_@D?AW\3O#^H)I-^^CZG\/_`!5X'\72>$M0
MTR[UTZ5;:IX:\5>"#>V>DB]O;/QK=7B164GV@#P,\$XX]_09K/$0]C+V4<51
MQ5.5JG/0E7]GS[6E#$4:%2-2.[YJ?PRA*,FI:51DJEY/#U*%2/[NU54O:<ON
MRLIT:E6$H2>JY:C7-%W2:`@'(P.>O%<^GA+PI'X@D\6Q^&?#Z>*Y;(:9+XG7
M1=.7Q#+IRF,BPDUH6PU*2R#0PD6K7)@!BC(3,:X_++]MC]M']H'P'\5-1^&W
M[(/@?PW\5]2_9G^'&E_M._MB:1>VNHZKJT?PBE\06]IH?P0\`OI=U!!IWQV^
M*W@O1_BKX]\$PZC'?RVEG\-M'BF\/ZE;^/M)EK]-_AQ\0/"'Q6\!>"_B9X`U
MVR\3>"?B!X7T'QGX3\0Z<7-CK7ASQ/I-GK>C:G;"1(Y4BO\`3[ZWNTBECBEC
M64I)&CJRC>O@<7A,+A\74<8TL9%\L85+U*<9*,J<,3!6=)XBDXUZ$:G\:B^>
M',D[94L7AL37JX>*<JF&:E></<DT^64J$WI4=&;]G5E#2G4?L^;F4DNV9588
M90P]&`(Z8Z'V)'T->3?\*"^!77_A2WPFSC'_`"3GP>/Y:-_^KM7SE_P4C_:!
M\?\`[+7[&OQ@^.GPO71&\<^"!X#_`+$7Q%I\VJZ*?^$D^)_@GPCJ0OM/AN[&
M2X']D:]?B#;=P^5=>1.=XB,3_<JC``_#&?3T_K_ABLXT\51PU/%TYSIT<17K
MX=.G4E&<JF$AAYSYHQM[JCC(<C;W<TDNNCE0JUYX>4(SJ4:=.L^>$9)0K2JQ
MCRMIZWH2YUI9<K=[H\YTGX._"/0+I+[0_A;\.M&OD(\N]TKP1X9T^\0JV\;;
MFSTN&9<,,C#\$`C!KT58T3(1%7/.%4#VZ`#H.!Z"N9\;:SJOASP?XJ\0Z'H%
MWXLUG0?#VL:QI/A:PE2"^\2:GIFGW%[8Z#93RI)%#=ZO<PPV%M-(CI%-<([(
MR@J?QH_8E_:3^/O[7VA_#GXAZ#^WS^S&?BG.-"\2?'G]B^+X%01:[\%M,:ZA
MTSXA?"S7=`O/C3I?QY\+?$#P-JJZEX<A^(?C&2?PMK/B'3H=0B\!_P!A:I;0
MUTT,%BL?A\1C*F(BJ&$E3A4J5Y8FJU*K&<X*U"AB94XM4I)U:WLJ,9\L74YF
MD85<5A\)5HX>-%^UKJ<HPI1HTTXTY0C)IU)TO:27M(WA3YYVO)1<5<_<"BD&
M,#'3`QCI_3^0^E+7EG>%%%%`!1110`5PWCSX8_#GXHZ4FA?$GP)X0\>Z/%(\
MT.F^+_#FD>(K2VG=#&UQ:1:M:72VESL)47-MY4ZCA9`.*[FB@#\[/%'_``2L
M_8H\1?;)K+X8:AX0OKR3SC>>$O&GBVR6WDZ_Z'I6I:MJWA^UC)_Y8PZ.L*Y8
MI&K'-?@[_P`%./C;\4?^"*?Q#^"?A']C'Q0QTS]ICP]XPU3XBR_%C1O#GCF\
MM9_A?JVA6GAB/PS+9:1X;BTR$P>/=<&II>6^IO>,;%HY+?[*PF_KUK^+?_@Z
MI_Y+;^P>/^I,^.I_\K_PK_P_E7W/AQ@,'F?%V78/'X:EB\+4I9A*I0KQ4Z4G
M2P&)J4W*+T?)4A"<;_:BCYOBS%8G!Y)7KX2M4H5XXC`QC5I.TU&IC*$)I-?S
M0E*+75.PWX+?\%;/V^_B-?V<FN_&ZUM[>Y=0^GZ5\,OA1:VH60%2%EN/!-YJ
M`8#HXO@0><9Z?M7^SW\2_B1\4_,U;QY\0O&NN7,]G<2RV\7B?6=$TB1Q`[@G
MP_X>N])T#:&`8Q_V8(VP-Z,.*_E4_8S\)>+?&>J6&G^#?"OB;QAJ,"PRRZ=X
M5T#5O$>H1H2<,]EHUG>W*@X)R8L;59\[5)']8W[)?P(^-NG:/:3:GX"N/"5G
M=V%L\6I>.+N+1B8+S[;:W:P^&K5K[Q<NKZ9Y45TVE>(='\*V5_;W,8MM>C<2
M^5]EQY@<FRV$Z>`PN78&KS145AZ="C5Y;J]G%*=EY/OH]3?**M:M2IRK5*E1
MN*=Y-N[]W?IT[>9\._M+:)`M]J=IHFC*^I:[JF%L=&TSS=1UW7-1DCLK2&*S
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MW46[7;Z-JVFZ73<*^-/VV/V>_%G[1_@KX-^&/"<OA>-O`?[57[,WQK\20^+)
M[V'3]0\$_!_XM>'_`!QXPTJSCL](UD7FM:CH6E7=IHVGWL%KIM]?S0V^H:GI
MEJTEW']ET5\[A<15P>(H8J@TJN'FJE-R7,E)72NM.CTLU;2UK&U>A3Q-&I0J
MING5BX32;3<7NDUJK]UJNC3,C2M$TC1+9;31](TS2+9&9TM=*L;2QMT>3&]U
MAM8H8PTORF3"Y)4;B>M:<@)B=1R2C@?BIQ^N!^IJ2BL;N]VVW=-MMMMKJV]6
M_-N_F:1C&*M%)+R5O7;ON^[U/D+]BCX#^*OV>?@/_P`*U\>2^&[_`,1'XR?M
M-?$-[GPU<7M_IIT;XR_M)?%?XP^%H&NM4TK1KPZI8^&/'>D6&N0FQ%K:ZW:Z
MC:Z?=ZE8PVVIW?*?L*_LU^/OV:=)_:DL/'VH>%]1E^-/[<7[4'[2/A$^%M0U
M2_CL/`'QF\;1^(?"6EZZ=5T/0VM/%%CIRB'6]/L(]2TJTN0(['6]2B/FC[HH
MKMK9AB:[QKJ2B_K]6-;$>[9<\:CJ1]FKVA%2;T2>CM<XZ6`P]%814XN/U*DZ
M5&S2]R5.%.2G9)R<E!-MN[E>]TVCXR_;K^!_Q;_:5^!LWP!^&7B?1O!7ASXN
M^+?#7@KX_P#BNZU>_P!*\5:?^S9J=RY^,>D?#1;;PUXEL+SX@^-O#,,W@+2Q
MK\6FZ-IFF>*-8UQ]26_TFPL[[YS^-?\`P2F^$WCGX"2?"KX?_$?]H3PAK?@/
M1]$U/]G:]U?]HKXU>+/"GP:^*/PWLXIO@KXST3P1KWC2_P##PA^'.O:=HUW8
MZ=;V,`73+2;3+.6R2=9(OU9HK7#9QF&"IT*6$KO#PH5Y8E*G%)U*TO9ISK-W
M]K:%*-.,9>Y&#FE&\YMSB,LP>+G5J8BFZLJM)47S2E:%-<SY::32C>4G-NS;
MDE*]XJWGWPG_`.%D_P#"L_`?_"XX?"5O\61X2\/I\2HO`-YJ=_X'_P"$X32[
M9/$\GA"[UO3=(UF7PY-K`NYM&_M73;/4$T][>*[A$Z.S?,GQ0_9@N?BC^V-\
M+OC3XGT3P)XH^$?A']F?X^?!GQ/X6\5VHUC4=5\0_%?QW\"/$6D36N@7VAW^
M@7OA^/0_AKXGT_79[_4[>Z274]/M+?3+^UO+^XL?MRBN:AC*V&K5L10<:=2M
M3Q-)\J<53ABJ<J52-*S3I\L)M4[/W-&M4C>MAJ5>G3I5DZD:<Z%1<[NY3H2C
M.#GTE>45SIJSN[):6^%/V,_V?/B[^RO_`,+&^!U[XCT7QC^RYX<UFTO_`-E.
MXO\`7M<U'XH?#;P)JD,MUJ7P/\61:EH@M=6\'?#;5F;3_A/XH/B[6_$4G@F>
MQ\,:_9VB>&--N[_V/]K;X6>)?CE^RU^TC\%/!]QI%KXL^+_P'^+GPP\,WFOW
M%Y::#9Z_X]\`Z_X6TBZUNZT^QU2_M=(@U#5+>749[+3-0NHK199+>QN95$+_
M`$1155,=B*N,6/DX?655I5Y3C!1C4KTN1NM."]V56M.'M:\K)U*DI2>ZLHX2
MC'"O!KG]@X3I*+G)RC3FG'DC)MR481?+35_<BHQ7NQ27XQ?M'?\`!,_Q]\:#
M^SY#X0^)=C\-]+U?X/>!/V5OV]M)TJ\\3QI\>/V7_"\NB>*KGPIX6O=-?3WT
M_P`86NOZ)XH^'6C>);NRT34H?A;\=/BCNU9;FSTKP]J'VK\,/V?-?\`_M?\`
MQO\`C9:1>%M.^&7CS]G7]F/X-^#/#^D27-MJ^C:C\$O%?[0FKZVESHL6CVNB
M:9X=.E?%7PO9^'!INK7DTDFGZM!/IVFVUK8RWOV11775SS,:^'>%JU8RHNC6
MH->S@G*%?%4,7)RDDI3G&>&H4J4YN3I8>G&C"T$CGIY5@Z56-:$)QJ1JTZT7
M[2;2G3H5<.DHM\JC*->K.I&*2J5IRJSO-W/*OC@OQ>D^$7Q%@^`:>#C\9[KP
MAKMG\,I_B#?:CI_@C3_&EYI\]MX?U;Q1-I&B^(=2ET;1]1D@U2^L;+2;FXU.
M&S;34:V%VUU!\`?"W_@D]\%/"7[/</P-\;?$;]HWQS;^*/"VMV/QLE3]I#XZ
M>&_#/QA\9?$.VN[GXS>+_$/@K3/B#_8L;_%/Q+K/B/7?$6F,+J!SK=S8RSW4
M:&1_U4HKFP^98S"4)4,+6>'C.O3Q,YTDHU9U*,91H7J6YN6@YU)4DK<LZDY-
MOW>76O@,+BJJJXBDJSC2E1C&HY.G&$Y1E4M!-*]3D@IMWO&$5;>_Q]^P]\(O
MC1^S]\!M&^!7QD\3Z+X\'PBUKQ%X#^$WC^PU:\U3Q%XN^`NAZ@\/P<NOB/!<
M^&/"]II7Q*T3P6VF^$O%EKHW]O:1J-SX>B\0P:_<7&MW5I8Y7[8G[+OB7X[O
M\%OBA\)/&VE_#/\`:0_9C\>:G\1O@CXU\0^'CXL\&W<OB3PMJG@7X@_#7XB>
M&X;JPU2^^'GQ0\$ZU?\`AS7[WPQJVB>+_#EY'HWBCP_JC7&BR:1J_P!K44O[
M0Q'UZ681]G#$3J5:DDJ5-T6Z\90KP=":E3]E6C.I"I2Y?9N%2<%%0Y8QIX.B
M\)'!OGE1A"E"%ZDG4BJ,HSI-5+\_/3<(.$^;FBX1DGS*[^`+KQA_P4QU^RL_
M#VF?`[]D#X5:S/?64&J?%'6?CY\5/C;X;T;3(K^#^TM3T;X1:9\"O@?KOC&_
MO=.%S_9^AZK\5_AW:V%W)&]UXBO(;<QWGWS&LFQ?-VF7C>5RJDXY*C<Y4'T+
M,?4GBIJ*QKUH5E&,,-A\-&/,W&A&I[[G:_/*O5K5))<JY8\_+#7EBN:5[I47
M2YN:O7K\R2_?2AHH[65.G3C?O)ISE]J3/S4\<_"O]KOP+^V;\6_VB?@9\,_V
M>/BGX/\`BQ\!/@'\*;C3/BM\??B#\&O$7AS7/@YXR^//B.^OK:V\+_LU?'+3
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M/@Q^W'^VI\._#G[./QK^&/[.?P1^$NM>/_A9XF^.7Q`\"_'3Q]\7O%NO^&?A
M5\0O#GQ+7PO\*/"&I_`WX666@WWCC7O!VAZ;>>+/&'BB_P#^$-T&\U?[)X4\
M5:H+*[A_6ZBM,)FF(P=.C"G"A.6&Q,L7A*M6G*=3"XF:HJ56DU.,)-^PHR4:
MT*M.,Z<91@GS<TU\OHXBI4J3G6C[>E"AB(0G&,*]&G*I*-.=X.44O;58MTI4
MYRC4:E)VC9B*51%)R515)/<@`$]^M?%/_!0S]G;QS^U7^R=\0O@5\.+[PWIO
MB_Q;XC^$&K:=?>+K[4M-\/PVW@#XU?#OXB:PM[>:/H^NZA%/<Z)X4U*WTY8-
M*N5FU*2SM[E[2VEFO+?[9HKDPV(J83$X?%4FO;8:M2Q%)SBI1]I2FIP<HO22
MYHJZ>C5T]&=->A#$4*N'J7]G6I3HS47RODG%QDDUMIM;MK=:#%R`!C'K_GCV
M['\*^,_^"A7[/7C?]JO]C[XQ?`+X<W_AK3/&?C^V\&1:+?>,+[4M-\.0/X=^
M(OA#Q;>_VE?:1H^OZC`LNF:!>PVQM](N]][);12^3"\EQ%]GT4L-7J87$4,5
M2:]KAJU*O2<HJ454HSC.'-%Z2CS05XO1ZI[A7HPQ%&K0G=4ZU*=&?*W&7)4@
MX2Y9+5/E;L][ZC$!"X.>GZ=OQ`_IQ7P+\=OV<?C+I_[1V@?MD?LN:UX(G^*T
M/PI@^!WQ4^$?Q<U/Q%H7PT^,WPRTKQ9J7C;P>(/&?A;2/%.K_#+XA>`_$7B#
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MDDATJ3I1:=:M5E)W<ZLH\RTLN50A"$4M_=@KO5W>I^4G[-?_``3AN_#'A?Q3
M\0/VA/BQ\6KO]J/XY^,=;^)_[0_B/X$?M"?'3X:_#C5/%^KW#V^A>&O">B:)
MXG\,R3>#/AGX*MO#WPX\&SZOIMOJ4OA_PW:W5S;V<]W-;1>L_L(_LN?$#]C:
MV^,7P(M=7TC6_P!E;2_B#+XN_9-MKKQ!J^M?$?X?>$O'-I_;_P`1?A9XQ&H>
M';"WF\/>&?B7-KNL?#G7/^$G\6Z[J'A[Q1+I>OW%@="T^.X_0*BN[$YUF.+A
MB:6(K*I2Q7L7*DX1]G2^KN*P_P!7BK*C["DGAJ2AI'#SE12Y+)<E'*\'AYT:
ME&$Z=2@JB4E4G>HJNM55;MJ:JU%&M--)2K1C4W1\/_\`!1G]G;X@_M7_`+'7
MQA^`GPNNO"=CX[\=6_@P^'KKQQJFJ:+X52Y\,?$CP=XRN(M8U31-!\4:K8PW
M6G^';NVAGL_#^J.MW-`)(!$TDD?6?"_QE^V[JOC72-/^,?[/O[,_@7X>S)J!
MUSQ1\.OVKOB;\3O%NGR1:;=2:6NF>"O$?['OPHTC5DO-62RLKYKKQWH[:=I\
M]SJ,$>I7%K%IMW]:45SQQLE@U@IT:%6E"M7KTI5(U/:4:N(AAZ=64)4ZM.+O
M'"TK*I&I&+3LK2:>\L)%XEXJ-2K3J2A2I5%#V;A4A1E5G3C)3ISDK.M4UA*$
MFI6OHK96M1ZM+I&IQZ#+I]OK;V%TNCW&KVL][I-OJA@?^SYM2LK2[L+N[L(K
MOR7O+:VOK.XN+=9(H+NWE9)4_%_X_P#[)W[7/[9.D_#'PO\`&SX"?L@?"'XC
M^"?''PR\3W/[9'PE^*?C+Q?\5O`D?P]\;^&O&>K:A^S[X;U_X`^&/$_A/5?'
M`T6]T2#2/$WQ;NM$\)Z?J]U_:US\0C;)'??MK1^?!SUJLOS&MEM3VV'A2=>+
M4J5:HJG/1DDTI0]G4IPFM;RIUXU:4[6J4YQ<HN<7@J>-C[.K.JJ;3C.G"45&
MHFT]>:,I0E%I.-2DZ=2#5XR3=Q!P.*6BBN`[`HHHH`****`"BBB@`K\@?VV?
M^"<_@?\`;L_;?_99\4_&?3Y]8^"'[/GPC^+&N^(_#5O>W>GCQIXW\8>,/AW:
M^"/#&I75DUM?0^'18^'O%FNZU+IM_:WLDVCZ1I4A;3]8NRGZ_4W&6_SV"_GU
M/YXKOR[,<7E6(>,P565#$1H8FC&M3=JE..*H3PU65.7V:GLJLU"2LXM\R::1
MR8S!T,=2C0Q,%4I>VHUG"7PREAZD:]-25U>*J4X2:V=K.Z;1RG@KP'X*^''A
MO3O!WP]\(^&O`OA+2(O(TCPQX0T+3/#?A_2X-Q8PZ?HVCVUGIUG$SDNT=O;1
M*SLSD;V)KK,#_P#5Q_+Z#\J6BN&3<Y.<VYSD[RG)N4FWJVY.[N^NNO7=G4HQ
MBDHI12T222279);!1112&%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
,%`!1110`4444`?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
